These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1012 related articles for article (PubMed ID: 33979771)

  • 21. Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.
    Mantero V; Baroncini D; Balgera R; Guaschino C; Basilico P; Annovazzi P; Zaffaroni M; Salmaggi A; Cordano C
    J Neurol; 2021 Jun; 268(6):2029-2030. PubMed ID: 32865629
    [No Abstract]   [Full Text] [Related]  

  • 22. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis.
    Mantero V; Abate L; Basilico P; Balgera R; Salmaggi A; Nourbakhsh B; Cordano C
    J Neurol; 2021 Jun; 268(6):2023-2025. PubMed ID: 32588182
    [No Abstract]   [Full Text] [Related]  

  • 24. Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak.
    Stojanov A; Malobabic M; Milosevic V; Stojanov J; Vojinovic S; Stanojevic G; Stevic M
    Mult Scler Relat Disord; 2020 Oct; 45():102407. PubMed ID: 32702641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review.
    Nabizadeh F; Ramezannezhad E; Kazemzadeh K; Khalili E; Ghaffary EM; Mirmosayyeb O
    J Clin Neurosci; 2022 Oct; 104():118-125. PubMed ID: 36029752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Location of first attack predicts the site of subsequent relapses in multiple sclerosis.
    Tsantes E; Leone MA; Curti E; Cantello R; Vecchio D; Granella F
    J Clin Neurosci; 2020 Apr; 74():175-179. PubMed ID: 32107149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis.
    Pasca M; Forci B; Mariottini A; Mechi C; Barilaro A; Massacesi L; Repice AM
    Mult Scler Relat Disord; 2021 Jan; 47():102591. PubMed ID: 33142245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.
    Fernández-Díaz E; Gracia-Gil J; García-García JG; Palao M; Romero-Sánchez CM; Segura T
    Mult Scler Relat Disord; 2020 Oct; 45():102402. PubMed ID: 32711297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with relapses in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
    Xie Y; Tian Z; Han F; Liang S; Gao Y; Wu D
    Medicine (Baltimore); 2020 Jul; 99(27):e20885. PubMed ID: 32629678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.
    Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Nimer FA; Sundström P; Gunnarsson M; Johansson R; Mellergård J; Rosenstein I; Ayad A; Sjöblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J
    Lancet Neurol; 2022 Aug; 21(8):693-703. PubMed ID: 35841908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Negative interpretation of ambiguous bodily information by patients with relapsing-remitting multiple sclerosis.
    Hosseinchi P; Ghalibaf E; Dehghani A; Khatibi A
    Mult Scler Relat Disord; 2022 Jun; 62():103808. PubMed ID: 35461059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depression, anxiety, and fear of COVID-19 in patients with multiple sclerosis in pandemic era: a cross-sectional study.
    Alirezaei M; Eskandarieh S; Sahraian MA; Naser Moghadasi A
    Neurol Sci; 2022 Jan; 43(1):59-66. PubMed ID: 34554334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.
    Möhn N; Saker F; Bonda V; Respondek G; Bachmann M; Stoll M; Wattjes MP; Stangel M; Skripuletz T
    J Neurol; 2020 Oct; 267(10):2803-2805. PubMed ID: 32494855
    [No Abstract]   [Full Text] [Related]  

  • 35. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.
    Zabalza A; Cárdenas-Robledo S; Tagliani P; Arrambide G; Otero-Romero S; Carbonell-Mirabent P; Rodriguez-Barranco M; Rodríguez-Acevedo B; Restrepo Vera JL; Resina-Salles M; Midaglia L; Vidal-Jordana A; Río J; Galan I; Castillo J; Cobo-Calvo Á; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
    Eur J Neurol; 2021 Oct; 28(10):3384-3395. PubMed ID: 33340215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
    Capone F; Ferraro E; Motolese F; Di Lazzaro V
    J Neurol; 2021 Sep; 268(9):3132-3134. PubMed ID: 33611610
    [No Abstract]   [Full Text] [Related]  

  • 37. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reliability of televisits for patients with mild relapsing-remitting multiple sclerosis in the COVID-19 era.
    Toscano S; Patti F; Chisari CG; Arena S; Finocchiaro C; Schillaci CE; Zappia M
    Neurol Sci; 2022 Apr; 43(4):2253-2261. PubMed ID: 35018548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis.
    Orefice N; Carotenuto A; Mangone G; Bues B; Rehm R; Cerillo I; Saccà F; Calignano A; Orefice G
    J Steroid Biochem Mol Biol; 2016 May; 159():1-7. PubMed ID: 26892094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How patients with multiple sclerosis acquire disability.
    Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
    Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.